2026 payer coverage update — GLP-1 formulary changes by insurer

hyun_seoul said:

Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the…

Can confirm. Same sequence, different timescale.

hyun_seoul said:

Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the…

There is a second half to this that has not been said yet. Practical: whatever you change, write down the date and the reason. In three months the reason is what you will have forgotten, and the reason is what makes the record worth having.

This was answered several pages up and is worth repeating rather than re-litigating:

Denials are usually procedural rather than clinical, and the order that works reflects that. Get the denial reason in writing, because it names the criterion you failed. Then supply the documentation that criterion asks for — usually documented BMI with a comorbidity, or a failed prior therapy. Then appeal, and ask for a peer-to-peer review, because a prescriber talking to a reviewing clinician resolves a large fraction of denials that written appeals do not. Manufacturer copay assistance is separate and applies mainly to commercial insurance, and patient assistance programmes are means-tested rather than a discount.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

A narrower follow-up, since the general answer is now clear:

Did your prescriber agree with that reading, and if not what was their objection?

Coming back to something from earlier in the thread, because it keeps being talked past:

Agreed, and the size of the effect matters as much as its existence. Something real and small gets treated here as though it were real and decisive.